Characteristics of 200 enrolled subjects
. | Hemophilia A, N (%) . | Hemophilia B, N (%) . | Total, N (%) . |
---|---|---|---|
Severe disease (FA < 1%)* | 79 (64.2) | 32 (41.6) | 111 (55.5) |
Moderate disease (FA 1-5%) | 44 (35.8) | 45 (58.4) | 89 (44.5) |
Race: white/African American/other | 106 (86.2)/17 (13.8)/0 | 71 (92.2)/4 (5.2)/2 (2.6) | 177 (88.5)/21 (10.5)/2 (1) |
Hispanic ethnicity | 5 (4.1) | 5 (6.5) | 10 (5) |
Mean/median age, years | 61/60 | 61/61 | 61/60 |
Use of prophylaxis | 42 (34.2) | 19 (24.7) | 61 (30.5) |
Current inhibitor | 8 (6.5) | 1 (1.3) | 9 (4.5) |
HCV*,† | 85 (69.1) | 39 (50.7) | 124 (62) |
HBV*,‡ | 6 (4.9) | 2 (2.6) | 8 (4) |
HIV* | 46 (37.4) | 8 (10.4) | 54 (27) |
. | Hemophilia A, N (%) . | Hemophilia B, N (%) . | Total, N (%) . |
---|---|---|---|
Severe disease (FA < 1%)* | 79 (64.2) | 32 (41.6) | 111 (55.5) |
Moderate disease (FA 1-5%) | 44 (35.8) | 45 (58.4) | 89 (44.5) |
Race: white/African American/other | 106 (86.2)/17 (13.8)/0 | 71 (92.2)/4 (5.2)/2 (2.6) | 177 (88.5)/21 (10.5)/2 (1) |
Hispanic ethnicity | 5 (4.1) | 5 (6.5) | 10 (5) |
Mean/median age, years | 61/60 | 61/61 | 61/60 |
Use of prophylaxis | 42 (34.2) | 19 (24.7) | 61 (30.5) |
Current inhibitor | 8 (6.5) | 1 (1.3) | 9 (4.5) |
HCV*,† | 85 (69.1) | 39 (50.7) | 124 (62) |
HBV*,‡ | 6 (4.9) | 2 (2.6) | 8 (4) |
HIV* | 46 (37.4) | 8 (10.4) | 54 (27) |